12.09.15
Genmab has reached $5 million milestone in its daratumumab collaboration with Janssen Biotech, triggered by progress in the ongoing Phase II study (Carina LYM2001) in NHL.
The study is evaluating daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). This milestone is related to progress in the arm of the study treating DLBCL.
Daratumumab has received Orphan Drug designation from the FDA for DLBCL, MCL and FL.
This Phase II study will enroll up to 210 patients with relapsed or refractory non-Hodgkin's lymphoma. Patients in the study will be treated with daratumumab monotherapy. The primary endpoint of the study is overall response rate.
The study is evaluating daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). This milestone is related to progress in the arm of the study treating DLBCL.
Daratumumab has received Orphan Drug designation from the FDA for DLBCL, MCL and FL.
This Phase II study will enroll up to 210 patients with relapsed or refractory non-Hodgkin's lymphoma. Patients in the study will be treated with daratumumab monotherapy. The primary endpoint of the study is overall response rate.